for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PAVmed Inc

PAVM.OQ

Latest Trade

3.95USD

Change

-0.08(-1.99%)

Volume

370,364

Today's Range

3.84

 - 

4.08

52 Week Range

1.64

 - 

6.59

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.03
Open
4.03
Volume
370,364
3M AVG Volume
98.14
Today's High
4.08
Today's Low
3.84
52 Week High
6.59
52 Week Low
1.64
Shares Out (MIL)
83.84
Market Cap (MIL)
337.89
Forward P/E
-9.71
Dividend (Yield %)
--

Next Event

Q1 2021 PAVmed Inc Earnings Release

Latest Developments

More

Pavmed Retires Convertible Debt

PAVmed Announces Pricing Of $45 Million Public Offering Of Common Stock

PAVmed Reports Proposed Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About PAVmed Inc

PAVmed Inc. is a medical device company organized to conceive, develop and commercialize a diversified pipeline of products. The Company's products include PortIO, Caldus, CarpX, NextCath, DisappEAR and NextFlo. PortIO is an implantable vascular access device, which does not require accessing the central venous system and does not have an indwelling intravascular component. CarpX is a percutaneous device to treat carpal tunnel syndrome. NextCath is a self-anchoring catheter, which does not require suturing, traditional anchoring techniques or add-on catheter securement devices. The Company's DisappEAR is an Antibiotic-eluting Resorbable Ear Tubes. The Company is engaged in developing and commercializing antibiotic-eluting resorbable ear tubes based on an aqueous silk technology conceived and developed at these institutions. The Company is engaged in developing disposable infusion system with variable flow resistors. Caldus is a disposable tissue ablation device.

Industry

Medical Equipment & Supplies

Contact Info

1 Grand Central Terminal Ste 4600

NEW YORK, NY

10017-5743

United States

+1.212.9494319

http://www.pavm.com/

Executive Leadership

Lishan Aklog

Chairman of the Board, Chief Executive Officer

Dennis M. Mcgrath

President, Chief Financial Officer and Corporate Secretary

Michael J. Glennon

Independent Vice Chairman of the Board

Brian J. DeGuzman

Chief Medical Officer

Debra J. White

Director

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.710

2019

-0.550

2020

-0.730

2021(E)

-0.415
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
789.03
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
-265.66

Latest News

Latest News

BRIEF-PAVmed To Join The Russell 2000 And Russell 3000 Indexes

* PAVMED - TO JOIN RUSSELL 2000, RUSSELL 3000 INDEXES EFFECTIVE AFTER U.S. MARKET OPEN ON JUNE 29 Source text for Eikon: Further company coverage:

BRIEF-Pavmed Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination For Esoguard Esophageal Dna Test

* PAVMED SUBSIDIARY LUCID DIAGNOSTICS RECEIVES PRELIMINARY PAYMENT DETERMINATION FOR ESOGUARD™ ESOPHAGEAL DNA TEST Source text for Eikon: Further company coverage:

BRIEF-Pavmed Says Executed LOI With Canon Virginia For DisappEAR™ Pediatric Ear Tubes

* PAVMED - EXECUTED LOI WITH CANON VIRGINIA TO DEVELOP, IMPLEMENT COMMERCIAL GRADE PROCESSES TO MANUFACTURE MOLDED RESORBABLE PEDIATRIC EAR TUBES

BRIEF-Pavmed Reports Q1 Adjusted Loss Per Share Of $0.10

* PAVMED REPORTS PRELIMINARY FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Pavmed Delays Filing Of 10-K - SEC Filing

* PAVMED DELAYS FILING OF 10-K - SEC FILING Source text: https://bit.ly/2JuuUgY Further company coverage:

BRIEF-PAVmed Announces FDA 510(K) Re-Submission For Its Carpx Minimally Invasive Carpal Tunnel Device

* PAVMED ANNOUNCES FDA 510(K) RE-SUBMISSION FOR ITS CARPX™ MINIMALLY INVASIVE CARPAL TUNNEL DEVICE

BRIEF-Pavmed Adds Esocure Esophageal Ablation Device With Patented Caldus Technology To Commercial Product Pipeline

* PAVMED ADDS ESOCURE™ ESOPHAGEAL ABLATION DEVICE WITH PATENTED CALDUS™ TECHNOLOGY TO COMMERCIAL PRODUCT PIPELINE

BRIEF-FDA Grants Pavmed Subsidiary Breakthrough Device Designation For Esoguard Esophageal DNA Test

* U.S. FDA GRANTS PAVMED SUBSIDIARY, LUCID DIAGNOSTICS, BREAKTHROUGH DEVICE DESIGNATION FOR ITS ESOGUARD ESOPHAGEAL DNA TEST Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up